Reactive antigen/antibody screen with a negative antibody differentiation assay
A 24-year-old man presents with 4 days of fever to 38.6 °C, sore throat, generalized lymphadenopathy, and a faint maculopapular rash on the trunk. He reports condomless anal sex with a new partner 12 days before symptom onset and has never been tested for HIV. A fourth-generation HIV-1/2 antigen/antibody combination immunoassay is reactive (signal-to-cutoff 12.3). The reflex HIV-1/HIV-2 antibody differentiation immunoassay is nonreactive. A quantitative HIV-1 RNA assay returns 48,000 copies/mL. CD4 count is 620 cells/µL. The patient is anxious and asks whether the first test could be a false positive. The clinic has same-day results and a link-to-care team but no on-site resistance testing.
1. Interpret the three results. Why does the differentiation assay disagree with the screen, and what is the diagnosis?
Read the worked answer
This is acute HIV-1 infection confirmed by nucleic acid testing.
The fourth-generation screen detects both p24 antigen and antibody, so it can turn reactive before antibody appears. The differentiation assay, by contrast, is antibody-only; in very early infection the antibody signal may still be absent or below the cutoff. The algorithm therefore directs any reactive screen with a negative or indeterminate differentiation result to an HIV-1 RNA test, which is exactly what resolves the discordance.
An RNA result of 48,000 copies/mL is far above the range of assay noise and, in a patient with a compatible febrile rash illness 12 days after exposure, establishes the diagnosis. A negative RNA result in the same scenario would have pointed to a false-reactive screen and prompted repeat serology in about 4 weeks rather than a diagnosis. The normal CD4 count does not argue against acute infection; CD4 counts fall later in the disease course.
2. What should the laboratory report and what immediate clinical actions follow from this result?
Read the worked answer
Report: issue a definitive report stating HIV-1 infection, acute/early, with the three component results and an interpretive comment explaining that the negative differentiation assay reflects seronegativity of early infection, not absence of infection. Do not report 'indeterminate' or 'HIV negative.'
Immediate actions:
- Same-day disclosure and linkage to care - acute infection with high viremia carries high transmission risk and warrants immediate antiretroviral initiation, often same-day.
- Baseline genotype for resistance before starting therapy; if on-site testing is unavailable, send out and start a regimen that does not depend on the pending result, then adjust.
- Confirm seroconversion with repeat fourth-generation testing at roughly 2–4 weeks, both to document the diagnosis in the record and to satisfy any local confirmation policy.
- Partner services and counseling on transmission risk during acute infection.
- Baseline laboratories for antiretroviral therapy (renal/hepatic function, hepatitis B and C, HLA-B*57:01 if abacavir is considered, STI screening).
A comment that antibody-based rapid tests may still be negative in this window is essential so that the patient is not given a false sense of reassurance by a later, unrelated negative rapid test.